

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number  
**WO 2005/092866 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 235/30**,  
A61K 31/4184, A61P 35/00

(21) International Application Number:  
PCT/PL2005/000022

(22) International Filing Date: 29 March 2005 (29.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P.366690 29 March 2004 (29.03.2004) PL

(71) Applicant (for all designated States except US): **FUNDACJA ROZWOJU DIAGNOSTYKI I TERAPII** [PL/PL]; ul. Słupecka 11 m 12, PL-02-309 Warszawa (PL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAZIMIERCZUK, Zygmunt** [PL/PL]; ul. Janowskiego 11/19, PL-02-784 Warszawa (PL). **PINNA, Lorenzo, A.** [IT/IT]; via V.E. Orlando 14, I-35-129 Padova (IT). **MEGGIO, Flavio** [IT/IT]; via Zago 12, I-35-128 Padova (IT). **ANDRZEJEWSKA, Mariola** [PL/PL]; ul. Nowoursynowska 161, PL-02-787 Warszawa (PL).

(74) Agent: **KIEWLICZ, Zofia**; Kancelaria Patentowa Kiewlicz Zofia, ul. J. Dąbrowskiego 79 m 5, PL-02-503 Warszawa (PL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**

- with international search report
- with amended claims

**Date of publication of the amended claims:** 17 November 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW DERIVATIVES OF 4, 5, 6, 7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION



(57) Abstract: New derivatives of 4, 5, 6, 7-tetrabromobenzimidazole of formula (I); wherein R<sub>1</sub> is hydrogen or aliphatic group, R<sub>2</sub> is aliphatic group optionally substituted with hydrogen or substituent such as hydroxyl group or substituted amino group and method of their preparation.




WO 2005/092866 A1

## AMENDED CLAIMS

[Received by the International Bureau on 04 October 2005 (04.10.05):  
original claims 1-21 replaced by amended claims 1-21 (2 pages)]


1. New derivatives of 4,5,6,7-tetrabromobenzimidazole of formula 1



Formula 1

wherein R<sub>1</sub> is hydrogen or methyl group, R<sub>2</sub> is (C<sub>1</sub>-C<sub>3</sub>)aliphatic group or (C<sub>1</sub>-C<sub>3</sub>)aliphatic group substituted at the position 2 with hydroxyl or dimethylamino group.

2. A new derivative according to Claim 1, which is 2-methylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
3. A new derivative according to Claim 1, which is 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
4. A new derivative according to Claim 1, which is 2-ethanolamino-4,5,6,7-tetrabromo-1H-benzimidazole.
5. A new derivative according to Claim 1, which is 2-isopropylamino-4,5,6,7-tetrabromo-1H-benzimidazole.
6. A new derivative according to Claim 1, which is 2-(2-hydroxypropylamino)-4,5,6,7-tetrabromo-1H-benzimidazole.
7. A new derivative according to Claim 1, which is 2-(2-dimethylaminoethylamino)-4,5,6,7-tetrabromo-1H-benzimidazole.
8. A method of preparation of new derivatives of 4,5,6,7-tetrabromobenzimidazole of formula 1, wherein R<sub>1</sub> is hydrogen or methyl group, R<sub>2</sub> is (C<sub>1</sub>-C<sub>3</sub>)aliphatic group or (C<sub>1</sub>-C<sub>3</sub>)aliphatic group substituted at the position 2 with hydroxyl or dimethylamino group in the reaction of the compound of formula 2,



Formula 2

## 13

wherein the substituent R<sub>3</sub> is halogen, alkylthio group or lower alkoxy group or other group easily being substituted, with an amine, at elevated temperature, and then the resulting product is purified by crystallization or chromatography on silica gel.

9. The method according to Claim 8 wherein in the compound of formula 2, the substituent R<sub>3</sub> is halogen consisting of Cl or Br, or alkylthio group consisting of CH<sub>3</sub>S, C<sub>2</sub>H<sub>5</sub>S, C<sub>3</sub>H<sub>7</sub>S, or (C<sub>1</sub>-C<sub>3</sub>)alkoxy group consisting of CH<sub>3</sub>O, C<sub>2</sub>H<sub>5</sub>O or other group easily being substituted consisting of (C<sub>1</sub>-C<sub>3</sub>)alkylsulfone group or (C<sub>1</sub>-C<sub>3</sub>)alkylsulfoxide group.
10. The method according to Claim 8 wherein as the amine, a primary (C<sub>1</sub>-C<sub>3</sub>)aliphatic amine is used.
11. The method according to Claim 10 wherein the primary (C<sub>1</sub>-C<sub>3</sub>)aliphatic amine includes in the aliphatic chain additionally hydroxyl groups or dimethylamino group.
12. The method according to Claim 8 wherein as the amine, a secondary (C<sub>1</sub>-C<sub>3</sub>)aliphatic amine is used.
13. The method according to Claim 8 wherein the amine is used both as a reagent and a solvent in an aqueous or alcoholic solution.
14. The method according to Claim 8 wherein the reaction of the compound of formula 2 with the amine is carried out within the temperature range from 80 to 140 °C.
15. The method according to Claim 8 wherein the compounds of formula 1 can be converted by a known method into salts of mineral or organic acids.
16. A pharmaceutical composition exhibiting anti-neoplastic activity, containing effective anti-neoplastic acting amount of the compound according to Claim 1, combined with at least one inert, pharmaceutically acceptable carrier or diluent.
17. A pharmaceutical composition exhibiting anti-neoplastic activity, containing effective, anti-neoplastic acting amount of the compound according to any one of Claims 2 - 7, combined with at least one inert, pharmaceutically acceptable carrier or diluent.
18. Use of new derivatives according to Claim 1 for manufacturing of a drug having anti-neoplastic activity.
19. Use of new derivatives according to any of the Claims 2 - 7 for manufacturing of a drug having anti-neoplastic activity.
20. A method of inhibiting caseine kinase activity 2 in patients in need of such treatment by administration of effective amount of the compound of formula 1 according to Claim 1.
21. A method of inhibiting caseine kinase activity 2 in patients in need of such treatment by administration of effective amount of the compound of formula 1 according to any of the Claims 2-7.